文献速递前列腺癌

阿比特龙联合泼尼松对比恩扎卢胺治疗转移性去势抵抗性前列腺癌的健康相关生活质量:一项II期随机试验结果

Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
PubMed 文献 · Eur Urol · 2018-12-24

该II期随机试验纳入202例转移性去势抵抗性前列腺癌患者,比较阿比特龙联合泼尼松与恩扎卢胺一线治疗对患者报告的生活质量、抑郁症状和认知功能的影响。结果显示,在≥75岁患者中,阿比特龙组FACT-P总分随时间改善优于恩扎卢胺组(p=0.003),而<75岁患者两组无差异(p>0.9);恩扎卢胺组在身体和功能健康领域出现临床意义恶化的比例更高。

要点

  • ≥75岁患者中阿比特龙组FACT-P总分改善优于恩扎卢胺组(p=0.003)。
  • 恩扎卢胺组身体和功能健康领域临床意义恶化比例更高(37% vs 21%,p=0.013;39% vs 23%,p=0.015)。
  • PHQ-9抑郁评分变化分布在第4、8、12周有利于阿比特龙组。

核心结论

  • 患者报告结局 favoring 阿比特龙 compared with 恩扎卢胺,差异见于FACT-P生活质量和PHQ-9抑郁评分。
  • FACT-P总分差异仅见于老年(≥75岁)患者亚组。

研究设计与样本

  • II期随机试验,纳入202例转移性去势抵抗性前列腺癌患者,一线接受阿比特龙或恩扎卢胺治疗(NCT02125357)。
  • 患者在基线和治疗期间完成FACT-P和PHQ-9问卷,以及MoCA认知评估。

主要发现

  • MMRM分析中,治疗组与年龄对FACT-P总分存在交互作用(p=0.048)。
  • ≥75岁模型中,阿比特龙组FACT-P较基线变化随时间优于恩扎卢胺组(p=0.003);<75岁模型无差异(p>0.9)。
  • 恩扎卢胺组身体健康领域临床意义恶化比例37% vs 阿比特龙组21%(p=0.013)。
  • 恩扎卢胺组功能健康领域临床意义恶化比例39% vs 阿比特龙组23%(p=0.015)。
  • PHQ-9评分较基线变化分布在第4、8、12周有利于阿比特龙组。

关键数值与推荐

  • FACT-P总分交互作用p=0.048。
  • ≥75岁患者FACT-P变化组间比较p=0.003;<75岁患者p>0.9。
  • 身体健康领域临床意义恶化比例37% vs 21%(p=0.013)。
  • 功能健康领域临床意义恶化比例39% vs 23%(p=0.015)。

临床怎么用

  • 对于≥75岁的转移性去势抵抗性前列腺癌患者,选择阿比特龙联合泼尼松可能较恩扎卢胺带来更好的生活质量。
  • 需关注恩扎卢胺治疗中身体和功能健康领域的临床意义恶化。
  • PHQ-9抑郁评分变化可辅助评估治疗对情绪的影响。

局限性

  • 这些分析非预设,结果应视为假设生成。
  • 研究为II期试验,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abiraterone and enzalutamide are associated with side effects that may impair health-related quality of life (HRQoL). OBJECTIVE: To assess patient-reported HRQoL, depression symptoms, and cognitive function for abiraterone versus enzalutamide. DESIGN, SETTING, AND PARTICIPANTS: We randomized 202 patients in a phase II study of abiraterone versus enzalutamide for first-line treatment of metastatic castration-resistant prostate cancer (ClinicalTrials.gov: NCT02125357). INTERVENTION: Patients completed Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Patient Health Questionnaire-9 (PHQ-9) questionnaires, and Montreal Cognitive Assessment (MoCA) cognitive assessments at baseline and on treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: To compare the change in FACT-P scores over time between treatment arms, we used a mixed model for repeated measures (MMRM). For FACT-P domains where there was an interaction between the treatment arm and age, we constructed separate models for patients aged <75 and ≥75yr. We compared the proportion of patients with clinically meaningful change from baseline for FACT-P, and the proportion of patients with an abnormal score and median change from baseline for PHQ-9 and MoCA using Fisher's exact test and Mann-Whitney U test. RESULTS AND LIMITATIONS: In the MMRM analysis, there was a positive test for interaction in the treatment arm by age for total FACT-P (p=0.048). FACT-P change from baseline over time was better for abiraterone than for enzalutamide in the ≥75-yr model (p=0.003), with no difference in the <75-yr model (p>0.9). A higher proportion of patients experienced clinically meaningful worsening with enzalutamide for the physical and functional well-being domains (37% vs 21%, p=0.013; 39% vs 23%, p=0.015). The distribution of change in PHQ-9 scores from baseline favored abiraterone at weeks 4, 8, and 12. These analyses were not prespecified, and results should be considered to be hypothesis generating. CONCLUSIONS: Patient-reported outcomes favored abiraterone compared with enzalutamide with differences in FACT-P HRQoL and PHQ-9 depression scores. Differences in the total FACT-P scores were seen only in the elderly patient subgroup. PATIENT SUMMARY: In this report, we examined the change in patient-reported quality-of-life scores from the start of treatment over time for patients treated with abiraterone versus enzalutamide for metastatic castration-resistant prostate cancer. We found that elderly patients treated with abiraterone had better quality of life over time, with no difference between treatments for the younger subgroup of patients.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Khalaf DJ, Sunderland K, Eigl BJ, et al. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. Eur Urol. 2018. PMID: 30591354. doi:10.1016/j.eururo.2018.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。